

## Research Article

## Open Access

## Innovative Medicines & Oncology Practice during Covid at MENA Regions Policy analysis

Abdalla Abotaleb PhD

WHO Project Manager Health, policy analysis expert &amp; Founder of MENA Network of Biologicals Stakeholders

**ABSTRACT**

Oncology practice during COVID -19 pandemic faced many challenges one of the major challenges is adaptation of treatment protocols for achieving following objectives. Managing system capacity, Enhancement of patient's outcomes (quality of life – economic value – clinical effectiveness). And utilizing the resources during this hard times. Previous objectives raised many questions about nature of treatment protocols should be implemented during COVID -19. Pandemic and how innovative medicines can achieve the previous objectives.

**\*Corresponding author**

Abdalla Abotaleb PhD, Health policy analysis expert Founder of MENA Network of Biologicals Stakeholders. E-mail: thepharmacist7777@gmail.com


Received: October 09, 2020; Accepted: October 14, 2020; Published: October 23, 2020

**Methods Integration Analysis between International Guidelines Like**

(ESMO, ASCO, NHS, WHO) and local guidelines .local survives with local oncologist at previous countries plus quality of life questionnaires for the patients were conducted. Cost Analysis from health systems for all oncology expenditures RESULTS innovative medicines had positive impact on Enhancement of patient's outcomes and resources utilization via implementation efficient Periodization criteria CONCLUSION Innovative medicines protocols changed the oncology practice during COVID -19 through Dynamic & efficient prioritization criteria which led to patient's outcomes ( quality of life – economic value – clinical effectiveness) enhancement plus Resources utilization.

**Objectives**




Oncology practice during COVID -19 pandemic faced many challenges one of the major challenges is adaptation of treatment protocols for achieving following objectives. Managing system capacity, Enhancement of patient's outcomes (quality of life – economic value – clinical effectiveness). And utilizing the resources during this hard times. Previous objectives raised many questions about nature of treatment protocols and policies should be implemented during (COVID -19) Pandemic and how innovative medicines can achieve the previous objectives. At MENA countries (Algeria, Morocco, Egypt, Lebanon, KSA, UAE and Turkey)





**Methods****Integration analysis between International guidelines like**

(ESMO, ASCO, WHO) and local guidelines local survives with local oncologist at previous countries plus quality of life questionnaires for the patients were conducted. Cost Analysis from health systems for all oncology expenditures. One way sensitivity analysis was conducted for all parameters affecting on practice adaptation to ensure validity and accuracy

**Results**

Innovative medicines had positive impact on Enhancement of patient's outcomes and resources utilization via implementation efficient Periodization criteria as following





### Discussion

This Research analyzing the impact on innovative medicines on oncology practice and patient's outcomes (quality of life – economic value – clinical effectiveness) during COVID -19 pandemic and what were the major Elements for that adaptation for giving recommendations to all stake holders at oncology field about how practice and system response to pandemic case in order to share knowledge to enhance system performance.

### Conclusion

Innovative medicines protocols changed the oncology practice during COVID -19 through Dynamic & efficient prioritization criteria which led to patient's outcomes (quality of life – economic value – clinical effectiveness) enhancement plus Resources utilization [1-5].

### Conflict of Interest

No conflict of interest

### References

1. World Health Organization (2020) Novel Coronavirus (COVID-19) Situation. who.int <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
2. Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer 23 March 2020 Version 2.
3. ESMO clinical guidelines for the management of non-coronavirus patients.
4. Wu Z, McGoogan, J M (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA <https://doi.org/10.1001/jama.2020.2648>.
5. ESMO (2020) The ESMO-MCBS Score Card [esmo.org https://www.esmo.org/guidelines/esmo-mcbs/esmo-magnitude-of-clinical-benefit-scale](https://www.esmo.org/guidelines/esmo-mcbs/esmo-magnitude-of-clinical-benefit-scale).

**Copyright:** ©2020 Abdalla Abotaleb, Wilfried. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.